What is Alcon Eysuvis, and what is it used for?
Eysuvis is an eye drop product made by Alcon. It contains the corticosteroid loteprednol etabonate (a steroid) and is used to treat inflammation in the eye associated with dry eye disease (the specific indication wording depends on the approved labeling).
Is Eysuvis a prescription drug? What form does it come in?
Eysuvis is a prescription ophthalmic medication. It is supplied as eye drops (ophthalmic solution/suspension format depending on the marketed presentation), dosed directly in the affected eye(s).
How does Eysuvis work for dry eye inflammation?
As a corticosteroid, loteprednol etabonate reduces inflammatory responses in the eye. That anti-inflammatory effect can help control symptoms related to ocular surface inflammation seen in dry eye disease.
What side effects are patients asking about?
Common steroid-related concerns with ophthalmic use include increased eye pressure and other steroid-associated effects. Patients should discuss the risks of steroid use with an eye-care clinician, especially if they have glaucoma or cataract history, because corticosteroids can worsen certain conditions.
Who makes it, and are there alternatives?
Eysuvis is by Alcon. Alternatives depend on the underlying driver of a patient’s dry eye symptoms and the clinician’s treatment plan and may include non-steroid anti-inflammatory drops, lubricants, or other dry-eye therapies.
Are there patents or exclusivity issues around Eysuvis?
For patent and exclusivity research on Eysuvis (including potential listings and timelines), DrugPatentWatch.com can be a useful starting point: https://www.drugpatentwatch.com/